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HLA antibodies (HLA ab) in transplant candidates have been associated with poor outcome. However, clinical relevance of noncy-
totoxic antibodies after heart transplant (HT) is controversial. By using a Luminex-based HLA screening, we retested pretransplant
sera from HT recipients testing negative for cytotoxic HLA ab and for prospective crossmatch. Out of the 173 consecutive patients
assayed (52±13𝑦; 16% females; 47% ischemic etiology), 32 (18%) showed pretransplant HLA ab, and 12 (7%) tested positive against
both class I and class II HLA. Recipients with any HLA ab had poorer survival than those without (65±9 versus 82±3%; 𝑃 = 0.02),
accounting for a doubled independent mortality risk (𝑃 = 0.04). In addition, HLA-ab detection was associated with increased
prevalence of early graft failure (35 versus 15%; 𝑃 = 0.05) and late cellular rejection (29 versus 11%; 𝑃 = 0.03). Of the subgroup of 37
patients suspected for antibodymediated rejection (AMR), the 9with pretransplantHLA abweremore likely to display pathological
AMR grade 2 (𝑃 = 0.04). By an inexpensive, luminex-based, HLA-screening assay, we were able to detect non-cytotoxic HLA ab
predicting fatal and nonfatal adverse outcomes after heart transplant. Allocation strategies and desensitization protocols need to
be developed and prospectively tested in these patients.
1. Introduction
Short- and long-term mortality after heart transplantation
(HT) has steadily decreased over time, reflecting the improve-
ments in perioperativemanagement and immunosuppressive
therapy [1]. Nevertheless, even in the context of modern
immunosuppressive strategies, the presence of preformed
anti-human leukocyte antigens (HLA) antibodies (ab) in
transplant candidates is still an important risk factor for allo-
graft rejection and graft loss [2, 3].
In the last decade, the classical detection method based
on complement dependent cytotoxicity (CDC) assays over
a panel of leukocytes (panel reactive antibodies—PRA) has
been replaced by more sensitive assays based on solid phase
recognition of circulating ab [4]. These techniques allow
detecting circulating anti-HLA ab in a higher number of
patients than CDC assays, thus raising concerns regarding
organ allocation and patient management during waiting list
[5]. However, in what way the information from solid phase
assays is translated into clinical practice to balance the risk
of inappropriately delaying transplant on the one hand, or
allocating organs likely to be affected by acute or chronic
antibody mediated rejection on the other, is still a matter of
investigation [4, 6]. Moreover, cost-effectiveness of the most
sensitive techniques based on single antigen detection, which
are also themost expensive, is poorly investigated in the heart
transplant setting [7].
Seeking to provide a background for clinical decision
making in patients with negative CDC, but with circulating
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HLA ab, we undertook this study to investigate the risk of
fatal and nonfatal posttransplant adverse outcomes in a series
of consecutiveHT recipients who received the graft before the
solid-phase technology become available in our center.
2. Methods
2.1. Study Design and Endpoints. We retested all the available
pretransplant sera of the recipients who had proved negative
in the classical PRA test and in CDC crossmatch with donor
lymphocytes at the time of transplantation, between 2000,
when we started routinely induction with thymoglobulins,
and 2005, before solid phase assays were available in our labo-
ratory. Thus, organ allocation or posttransplant management
was not influenced by knowledge of circulating anti-HLA ab
in these patients.
Clinical charts were reviewed to assess demography and
study outcomes that comprised overall survival, early graft
failure, early and late cellular rejection, and pathological
antibody-mediated rejection (AMR) [8]. Figure 1 shows a
flow chart of the study and the number of patients in whom
it was possible to assess each of the outcomes.
Early graft failure (EGF) was defined as a need for post-
operative mechanical support (either extracorporeal mem-
brane oxygenation (ECMO) or intra-aortic balloon pump
(IABP)) or 30-day death/retransplant.
2.1.1. Cellular Rejection. All patients were routinely moni-
tored for cellular rejection with scheduled endomyocardial
biopsies (EMB) performed during the first five posttransplant
years. EMB performed before 2006 were graded according to
the 1990 ISHLT grading [9], while a new grading system [10]
was followed for EMB performed from 2006 on. For study
purposes, we report the incidence of clinically meaningful
rejection as the occurrence of EMB graded 3A/2R or greater.
We defined as late rejection the detection of a 3A/2R or greater
grade after the first posttransplant year.
2.1.2. Antibody-Mediated Rejection. AMR was not routinely
monitored in study patients. Following the first official
consensus document dealing with the diagnosis of AMR in
heart transplant recipients published in 2005 [10], only EMBs
performed after 2005 were routinely screened for patho-
logical AMR. Immunohistochemistry for C4d on paraffin
embedded sections was performed only in biopsies with late
cellular rejection, or histological picture suggestive of AMR,
or in presence of hemodynamic compromise (i.e., capillary
wedge pressure≥18mmHg, or drop in ejection fraction≥15%,
or symptoms of hear failure) [11]. Thus, we are able to report
the incidence of pathological AMR (pAMR) only in the
subgroup of patients who underwent complete immunohis-
tochemistry stainings (Figure 1). Following the most recent
ISHLT consensus criteria for the diagnosis of pAMR [8],
EMB with full histological and immunohistochemistry AMR
assessment have been reviewed and graded accordingly, by an
experienced pathologist (O. Leone) who was blinded to the
anti-HLA assessment.
This study complies with national ethical rules and regu-
lation for investigations on human subjects.
sera not available
entered the study
monitored for year 
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Figure 1: Study flow chart.
2.2. Antibody Detection. At time of listing, all patients were
prospectively typed at the HLA-A, HLA-B, and HLA-DR loci
by serological or molecular biology techniques and received
antibody screening by classical PRA cytotoxicity assay, which
resulted negative in all patients included in the current study
[12]. At time of transplant, CDC donor crossmatch tested
negative in all cases.
In all consecutive patients with serum availability
(Figure 1), we re-tested the sera to identify IgG anti-HLA
reactivity by a bead-based screening assay on the Luminex
platform (LABScan 100). We used the Labscreen mixed kit
(One Lambda, Inc., Canoga Park, CA, USA) following the
manufacturer’s instructions. Briefly, Labscreen simultane-
ously detects class I and class II antibodies by a pool of
microbeads coated with purified class I an class II antigens.
Collectively, there are beads representing 96 class I (A, B,
C) and 56 class II (DR, DQ, DP) antigens/alleles. Patient
serum was incubated with the beads at room temperature
in the dark for 30 minutes, washed twice and subsequently
incubated with phycoerythrin-conjugated anti-human IgG
in the dark with gentle shaking for 30 minutes, washed
twice, and analyzed in the Luminex platform. In the assay,
antibodies are detected by the fluorescence intensity (FI) of
eachHLA antigen coated bead. Normalizedmean fluorescent
indexes (MFI) from Fusion software (One Lambda, Inc.)
were used to assign positive antibodies (MFI > 500). This
assay detects all HLA IgG-binding antibodies and is unable
to discriminate single antigen type [13].
While not providing HLA specificity of the detected
antibody, this test is available at a cost of 30 C/test, as opposed
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to the single bead HLA assay, which allows detecting HLA
specificity for about 600 C/test.
2.3. Immunosuppressive Therapy. Standard immunosuppres-
sive protocol consisted in induction with low-dose thymo-
globulins (0.75 to 1mg/Kg/day for 3–5 days) followed by
maintenance therapy based on cyclosporine, azathioprine
(AZA), and prednisone (0.2mg/Kg/d, tapered off in patients
with no rejection). After November 2004, AZA was substi-
tuted by mycophenolate mofetil (MMF) for routine practice.
Cellular rejection graded 3A (2R) or greater was treated
with 1 g/day for three days with methyl-prednisolone i.v.,
or with thymoglobulin if associated with hemodynamic
compromise or steroid resistant.
Treatment of AMR was not standardized and often
depended on treating physician. Mostly, patients with patho-
logical signs but no symptoms were not treated or received
uptitration of maintenance immunosuppression. Patients
with pAMR and clinical or instrumental signs of graft dys-
function received plasmapheresis and IVIG. One case of
relapsing AMR received rituximab. This strategy was in
line with current practice in most of transplant centers, as
reported by a recent survey conducted within ISHLT [14].
2.4. Statistical Analysis. Continuous variables are reported as
means ± standard deviation, categorical variables as numbers
(percentages). Student’s 𝑡-test or Chi-Square tests were used
as appropriate to assess differences between groups. Overall
survival was assessed by Kaplan-Meier method and differ-
ences between groups with log-rank test. The association of
anti-HLA ab with study outcomes was adjusted for potential
confounders by using Cox proportional hazards method (for
all-cause death and cellular rejection) or by logistic regression
(for EGF). A 𝑃 value < 0.05 was considered as significant.
3. Results
3.1. Study Population and Prevalence of Anti-HLA ab. Out of
the 173 recipients fulfilling inclusion criteria, 32 (18%) were
found to have circulating pretransplant HLA ab. Of these,
28 (87%) showed ab against class I HLA antigens, 16 (50%)
against class II, and 12 (38%) tested positive for ab against
both class I and class II HLA antigens. As expected, female
patients presented HLA ab more often than males (Table 1),
with 10 (83%) of them reporting previous pregnancies. While
not significantly associated with HLA ab in the overall study
population (Table 1), previous heart surgery appeared to favor
HLA sensitization in males, because HLA ab was detected in
10 (21%) of the 47 patients with previous heart surgery versus
in 9 (9%) of the 96 without (𝑃 = 0.05). MMF, routinely
introduced after November 2004, was less often used in
patients with HLA ab. During the study period, none of the
recipients had received a ventricular assist device implant
before transplant.
3.2. Anti-HLA ab and All-Cause Mortality. Overall, during
the 6-year study follow-up, 36 patients died and one was
retransplanted, accounting for an estimated graft survival of
78 ± 3%. Patientswith pretransplantHLAab had significantly








Age (y) 55 ± 13 52 ± 13 0.2
Sex (females %) 12 (38%) 15 (11%) <0.01
Pre-transplant CAD (%) 16 (50%) 65 (46%) 0.7
Donor age (y) 35 ± 12 34 ± 13 0.7
Donor sex (females %) 5 (16%) 40 (29%) 0.1
Donor cause of death (stroke %) 15 (48%) 45 (33%) 0.1
Pre-transplant heart surgery (%) 13 (41%) 42 (30%) 0.2
Cold ischemic time 187 ± 41 190 ± 51 0.7
Started on MMF versus AZA (%) 3 (9%) 32 (24%) 0.05
worse survival than those without (65 ± 9 versus 82 ± 3%;
𝑃 = 0.02; Figure 2(a)). Furthermore, patients with both class
I and class II HLA showed even poorer estimated survival
(55 ± 15%; Bonferroni 𝑃 = 0.04 versus ab negative patients)
while those with either anti class I or class II alone, showed an
intermediate estimated survival (Figure 2(b)). In themajority
of cases, death was attributed to graft-related causes (18 (49%)
including CAV, sudden death, rejection, and unspecified
graft failure), followed by infection (21%), malignancy (11%),
and others (16%). Causes of death did not appear different
between patients with and without anti-HLA ab (𝑃 = 0.9).
Multivariable analysis showed that the negative effect of
pretransplant HLA ab on survival persisted after adjusting
for recipient’s gender and for pretransplant cardiac surgery,
the two factors we found to be associated with anti HLA
ab development (adjusted RR (95% CI) = 2.4 (1.03–5.12);
𝑃 = 0.04). Of note, the use of MMF as well did not appear
to influence the negative effect of anti-HLA ab on survival
(adjusted RR (95% C.I.) = 2.23 (1.04–4.52); 𝑃 = 0.04).
3.3. Anti-HLA and Other Graft-Related Outcomes. EGF
occurred in 18 (10%) patients (10 in-hospital deaths, 5 ECMO,
3 IABP). Patients with any positive anti-HLA ab (22% versus
8%; 𝑃 = 0.03, Figure 3), as well as female recipients (31%
versus 7%; 𝑃 < 0.01), were more likely to develop EGF. After
factoring both variables into a multivariable logistic model,
only female gender resulted independently associatedwith an
increased risk for EGF (adjusted OR (95% CI) = 4.84 (1.54–
14.9); 𝑃 < 0.01).
Cellular rejection was routinely monitored with sched-
uled endomyocardial biopsies for the first 5 years after
transplant. As shown in Figure 1, 164 patients survived long
enough to receive a biopsy during year 1, and 155 patients
received at least one biopsy during years 2 to 5. While pre-
transplant anti-HLA ab did not seem to influence year 1
CR, they were associated with a higher incidence of late
CR (Figure 3). Of note, multivariable analysis showed that
recipient’s female gender or therapywithMMFdidnot appear
to influence the impact of pretransplant anti-HLA ab on the
risk of late CR (adjusted RR (95% C.I.) = 2.49 (1.18–4.97);
𝑃 = 0.02).
Complete histological and immunohistochemistry diag-
nosis of pAMR was available in only 37 patients (Figure 1)
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Figure 2: Kaplan-Meier estimate survival in patients with HLA ab. (a) Overall survival in patients with (solid line) and without (dotted line)
pretransplant HLA ab. Vertical lines indicate standard errors of the survival estimate. (b) Overall survival according with HLA antibodies
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Figure 3: Kaplan-Meier estimate of freedom from cellular rejection. (a) Survival free from cellular rejection graded ≥3A/2R on surveillance
endomyocardial biopsies performed during year 1 in patients with or without pretransplant HLA ab. (b) Survival free from cellular rejection
graded ≥3A/2R on surveillance endomyocardial biopsies performed after year 1 in patients with or without pretransplant HLA ab.
in EMB performed 62 ± 27 months after transplant. Of
those, 9 (24%) hadpretransplant anti-HLAab. Figure 4 shows
the distribution of pAMR grade between the two groups
of patients. Interestingly, while the prevalence of a negative
biopsy was similar between the study groups, pAMR grades 1
and 2 differed significantly, with pAMR2beingmore frequent
in patients with anti-HLAab (Bonferroni adjusted 𝑃 = 0.04).
4. Discussion
Since the late sixties, pretransplant anti-HLA sensitization
has been associated with high risk of graft loss, so it was
deemed unacceptable to allocate organs across a positive
crossmatch [15]. Traditional PRA assays allow us to estimate
the probability of listed patients receiving a graft expressing
HLA antigens which the patients are primed against, limiting
organ allocation only after a negative CDC prospective cross-
match (usually for patients with PRA >10%). Indeed, elevated
PRA was found to be an independent risk factor for graft loss
in a large number series of heart transplant recipients [3].
The use of the more sensitive solid phase assays, which allows
detection of noncytotoxic circulating anti-HLA ab [4], and
the increased referral of patients with previous cardiothoracic
surgery (i.e., extreme heart failure surgery and mechanical
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Figure 4: Anti-HLA ab and pAMR. Distribution of pAMR grades
in patients with and without pretransplant HLA ab.
circulatory supports) markedly enhanced the rate of heart
transplant candidates detected with anti-HLA antibodies. To
what extent these pre-formed antibodies identify unaccept-
able risk for organ allocation is still a matter of debate [2, 16–
18], and current consensus in heart transplantation is mainly
based on a few single center experiences [16]. Moreover, the
high cost of the most sensitive techniques may limit the
applicability of a thorough anti-HLA ab screening in a setting
of limited healthcare resources.
In this study, by re-testing with a low-cost Luminex-
based assay the pretransplant sera froma series of consecutive
recipients who had a negative PRA as evaluated with CDC
testing, we identified a subgroup of patients with noncyto-
toxic anti-HLA ab who showed increased risk of death and
nonfatal adverse events during the posttransplant follow-up,
independently from immunosuppressive strategy and other
possible confounders.
In line with other published series, we found that about
1 in every 5 patients showed either class I or II noncytotoxic
anti-HLA ab before transplantation, [2] with female gender
and previous cardiothoracic surgery being the major risk
factors for their development. Detection of anti-HLA ab and
in particular of antibodies against both class I and II HLA
was independently associated with increased risk of all-cause
mortality, up to 6 years after transplant. Lack of differences in
specific causes of death between sensitized and not sensitized
patients raises the hypothesis that pretransplant anti-HLA
antibodies may represent a generic marker of posttransplant
risk, not only involved in the specific immunologic pathways
of antibody-mediated rejection.This concept is supported by
the finding that despite eliciting more powerful immunosup-
pression, the use of MMF instead of azathioprine did not
influence the mortality risk associated with anti-HLA ab.
Nevertheless, we cannot exclude that limited sample size, and
timing of the deaths observed in the anti-HLA ab patients,
mostly occurring early after transplant, could explain lack of
MMF benefit.
Although early mortality appeared to be themajor threat,
late cellular rejection, as detected by protocol biopsies,
occurred more frequently in sensitized patients surviving
longer than one year after transplant. This finding supports
the concept of a strict interplay between circulating anti-
bodies and cellular rejection, with alloantibodies behaving
as opsonins facilitating T-cell activation and limiting the
development of tolerance towards the graft [19]. In addition,
as a possible consequence for clinical practice, detection of
pretransplant HLA ab may help to identify patients in whom
biopsy surveillance may be required even after the first post-
transplant year [20].
Only a small group of patients was assessed for patho-
logical signs of AMR, in biopsies performed after 2005, [10]
and the lack of comprehensive pathological and serological
AMR monitoring in most of the study patients reduces the
ability of our results to provide robust correlations between
the pathological AMR grading and HLA ab. Nevertheless,
in a subgroup of 37 patients we were able to find suggestive
evidence correlating pAMR grading with pretransplant HLA
ab. In particular (Figure 4), circulating HLA ab appeared to
be associated with pAMR 2 (i.e., coexistence of histological
damage and C4d activation) but with EMB with either histo-
logical or C4d criteria only (i.e., pAMR1). To our knowledge,
this is the first observation linking the new pathological
classification to serological markers of AMR [8].
4.1. Study Limitations. Retrospective design may represent a
limitation of this study.However, by re-testing sera of patients
who at the time of transplant were managed without the
awareness of HLA antibodies, we provide an analysis of the
effect of HLA pre-sensitization on outcome that is unbiased
bymedical treatment or organ allocation approach. Although
allowing the simultaneous detection of noncytotoxic class I
and class II HLA ab, the solid-phase assay used in this study
does not provide single HLA antigen specificity, restraining
us from providing an analysis of the impact of donor-specific
antibodies, as opposed to any anti-HLA ab. We believe that
this potential study limitation is counterbalanced by the low-
cost of this assay that retains the ability to independently
stratify posttransplant prognosis, helping to direct resources
to selected group of high-risk patients.
5. Conclusions
This observational study shows that noncytotoxic HLA anti-
bodies identify heart transplant candidates at high risk of
death, early graft failure, and of late cellular and antibody-
mediated rejection, underscoring the need for an accurate
screening of HLA ab in heart transplant candidates. The
ability of a low-cost assay to stratify prognosis may help to
increase the feasibility ofHLAabdetection even in a setting of
low-resource healthcare systems. In addition, in a subgroup
of patients, we provide first-time association between HLA
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ab and the recent pathological grading of AMR. Although
prospective validation of specific strategies to manage sensi-
tized heart transplant candidates is still lacking, our findings
support the concept that approaches involving desensitiza-
tion protocols, [21] allocation based on virtual crossmatch,
[22], and customized immunosuppressive strategies may
improve posttransplant outcome in these patients.
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